Vanguard Group
GTBP icon

Vanguard Group’s GT Biopharma GTBP Stock Holding History

Vanguard Group’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-420
Closed -$6.25K – 4360
2025
Q3 		$6.25K Hold
420
– – ﹤0.01% 4342
2025
Q2 		$37.6K Hold
420
– – ﹤0.01% 4212
2025
Q1 		$23.5K Hold
420
– – ﹤0.01% 4234
2024
Q4 		$32K Hold
420
– – ﹤0.01% 4237
2024
Q3 		$24.1K Hold
420
– – ﹤0.01% 4291
2024
Q2 		$29.7K Sell
420
-400
-49% -$35.8K ﹤0.01% 4335
2024
Q1 		$90.9K Sell
820
-631
-43% -$83.3K ﹤0.01% 4253
2023
Q4 		$277K Buy
1,451
+1
+0.1% +$183 ﹤0.01% 4172
2023
Q3 		$262K Sell
1,450
-16
-1% -$3.31K ﹤0.01% 4202
2023
Q2 		$343K Sell
1,466
-37
-2% -$9.6K ﹤0.01% 4213
2023
Q1 		$620K Hold
1,503
– – ﹤0.01% 4060
2022
Q4 		$999K Hold
1,503
– – ﹤0.01% 3916
2022
Q3 		$1.98M Buy
1,503
+1
+0.1% +$1.91K ﹤0.01% 3745
2022
Q2 		$3.37M Buy
1,502
+185
+14% +$350K ﹤0.01% 3570
2022
Q1 		$2.84M Sell
1,317
-291
-18% -$642K ﹤0.01% 3800
2021
Q4 		$3.68M Buy
1,608
+324
+25% +$1.21M ﹤0.01% 3780
2021
Q3 		$6.49M Sell
1,284
-26
-2% -$196K ﹤0.01% 3500
2021
Q2 		$15.2M Buy
1,310
+953
+267% +$9.9M ﹤0.01% 2984
2021
Q1 		$1.83M Buy
+357
New +$1.56M ﹤0.01% 3880

Other funds holding GTBP

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Scientech Research LLC
Scientech Research LLC Jersey City, New Jersey $123M AUM 198.31% 1-Year Est. Return
SeaCrest Wealth Management
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Integrated Wealth Concepts
Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Coston McIsaac & Partners
Coston McIsaac & Partners Bar Harbor, Maine $497M AUM 11% 1-Year Est. Return
Caitlin John
Caitlin John Brighton, Michigan $183M AUM 30.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Group's GTBP Position: Q4 2025 in Review

Vanguard Group sold out of GT Biopharma (GTBP) in Q4 2025, closing a stake of 420 shares — an estimated $6.25K sold.

Vanguard Group first reported a position in GTBP in Q1 2021 and held it in 19 quarters. The position peaked at $15.2M in Q2 2021. 34 funds tracked by Wall St. Rank hold GTBP as of Q4 2025.

  • Vanguard Group reported no remaining GT Biopharma position as of Q4 2025 after selling out during the quarter.
  • Vanguard Group sold 420 GT Biopharma shares in Q4 2025, an estimated $6.25K.
  • Vanguard Group first reported a position in GT Biopharma in Q1 2021 and held it in 19 quarters.
  • Vanguard Group's GT Biopharma position peaked at $15.2M in Q2 2021.
  • 34 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.